EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Physiologically Based Pharmacokinetic Model of Brigatinib in Healthy Volunteers and Patients With Cancer

Yichao Xu iD, Xinhua Hu iD, Pengfei Zhao iD, Lu Wang iD, Zourong Ruan iD, Bo Jiang iD, Honggang Lou iD

CPT: Pharmacometrics & Systems Pharmacology · 2026-08 · 15 (8)

DOI: 10.1002/psp4.70302 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 21.07.2026. Verfasst von Yichao Xu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center of Clinical Pharmacology, Second Affiliated Hospital of Zhejiang University, Hangzhou, China. Hauptthemen laut MEDLINE: Models, Biological, Organophosphorus Compounds, Pyrimidines, Antineoplastic Agents. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Brigatinib, an oral ALK inhibitor for metastatic NSCLC, lacks dosing guidance for special populations such as the Chinese. This study developed a physiologically based pharmacokinetic (PBPK) model using European data from patients with hepatic/renal impairment and drug–drug interaction (DDI) studies (itraconazole, rifampin). The model was then applied to predict (1) pharmacokinetics (PK) in the Chinese population; (2) PK in Chinese patients with hepatic/renal impairment; and (3) DDI in Chinese patients. Validated against clinical data, the model successfully predicted brigatinib PK alone and with CYP3A4 modulators. Food simulations showed a slight absorption delay without clinically meaningful exposure reduction. In hepatic/renal impairment, the model accurately predicted exposure changes across severity groups (fold error < 2). Extending the European‐validated model to Chinese populations, the findings demonstrate reliable predictions of brigatinib PK in Chinese individuals as well as in Chinese patients with hepatic or renal impairment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Models, BiologicalOrganophosphorus CompoundsPyrimidinesAntineoplastic AgentsProtein Kinase InhibitorsHumansDrug InteractionsFemaleMaleAdultMiddle AgedAsian PeopleHealthy VolunteersRifampinAgedLiver DiseasesYoung Adult

Stichwörter der Autor:innen

Chinese populationbrigatinibdrug–drug interactionshepatic or renal impairmentphysiologically based pharmacokinetic model

Substanzen

brigatinibOrganophosphorus CompoundsPyrimidinesRifampinAntineoplastic AgentsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Center of Clinical Pharmacology, Second Affiliated Hospital of Zhejiang University, Hangzhou, China.

ORCID-Profile: Yichao Xu, Xinhua Hu, Pengfei Zhao, Lu Wang, Zourong Ruan, Bo Jiang, Honggang Lou

Zitieren

APA

Xu, Y., Hu, X., Zhao, P., Wang, L., Ruan, Z., Jiang, B., & Lou, H. (2026). Physiologically Based Pharmacokinetic Model of Brigatinib in Healthy Volunteers and Patients With Cancer. CPT: Pharmacometrics & Systems Pharmacology, 15(8). https://doi.org/10.1002/psp4.70302

Vancouver

Xu Y, Hu X, Zhao P, Wang L, Ruan Z, Jiang B, et al. Physiologically Based Pharmacokinetic Model of Brigatinib in Healthy Volunteers and Patients With Cancer. CPT: Pharmacometrics & Systems Pharmacology. 2026;15(8). doi:10.1002/psp4.70302

BibTeX
@article{Xu2026,
  author = {Xu, Yichao and Hu, Xinhua and Zhao, Pengfei and Wang, Lu and Ruan, Zourong and Jiang, Bo and Lou, Honggang},
  title = {Physiologically Based Pharmacokinetic Model of Brigatinib in Healthy Volunteers and Patients With Cancer},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2026},
  volume = {15},
  number = {8},
  doi = {10.1002/psp4.70302}
}
Kostenlos starten →